Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | ASCEMBL: asciminib versus bosutinib in third-line treatment of CP-CML

Michael Mauro • 18 Dec 2023
ASH 2023
Chronic Myeloid Leukemia Leukemia Asciminib Bosutinib
ASCEMBL

Michael Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase III ASCEMBL trial (NCT03106779), comparing the safety and efficacy of asciminib versus bosutinib for the treatment of patients with chronic phase chronic myeloid leukemia (CP-CML) who have received two or more previous lines of therapy. After a median follow-up of four years, the safety and efficacy of asciminib were superior, with evidence of greater therapeutic benefit when it is used earlier in treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Memorial Sloan Kettering Cancer Center: Institutional Research Funding; Novartis: Consulting/Advisory Honorarium.

More from Michael Mauro

6:31
An overview of trials investigating asciminib in the treatment of Ph+ CML
Michael Mauro • 18 Dec 2023
1:14
Unmet needs in pediatric CML
Michael Mauro • 22 Oct 2022
1:52
ESH CML session highlights: pediatrics, biomarkers, and COVID
Michael Mauro • 22 Oct 2022
1:42
Managing cardiovascular risks associated with lifelong TKI therapy in CML
Michael Mauro • 22 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals